noom glp-1 rx Access and Transparency Noom Enters Longevity Health Space
Description
New ethics disclosures show the president invested in Eli Lilly and a company that manufactures injectable devices as his health agencies implemented policies that benefited them.
In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 percent of their body weight.
Discover what clinical research reveals about joint discomfort during Ozempic, Wegovy, or Rybelsus treatment, potential causes, and when to seek medical evaluation.
Amylin mimetics have potential as therapies for obesity and diabetes mellitus, but clinical development has proven challenging
Moonshots for Health 2025 is the premier virtual conference on the future of metabolic health
Unlike FDA-approved medications (e.g., Wegovy, Ozempic, Zepbound), compounded alternatives lack agency review for safety, quality, and efficacy
